Biodesix, Inc. (BDSX)
Nasdaq: BDSX · Services-Medical Laboratories · Louisville, CO · filing with the SEC since 2008
Filings
228 filings since 2017 beside 353 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 36 days after the quarter ended. The proxy statement was last filed Apr 9, 2026.
Filings a yearinsider forms included
252501061111207064
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 2 times in the last 36 months, the newest Nov 5, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Mar 28, 2025.SEC letters: 10 in the last 36 months, the newest May 27, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Sep 15, 2025
8-K items 3.03, 5.03, 9.01
Change to shareholders' rights; Charter, bylaw or fiscal-year change · Current report
Sep 12, 2025
40 of 228 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.